Inotuzumab ozogamicin

Inotuzumab ozogamicin (CMC-544) is an anti-CD22 antibody-drug conjugate (ADC) . Inotuzumab ozogamicin consists of a humanized IgG4 anti-CD22 mAb, covalently linked to Calicheamicin (HY-19609) via an acid-labile AcBut (HY-132261) linker. The antibody portion is Inotuzumab (HY-P99264), and the drug-linker conjugate for ADC is N-Ac-γ-Calicheamicin-AcBut-NHS ester (HY-103688) . Inotuzumab ozogamicin binds to the minor groove of DNA, inducing double-strand cleavage and subsequent apoptosis. Inotuzumab ozogamicin can be used for the study of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) [1].

Product Specifications

CAS Number

[635715-01-4]

Product Name Alternative

CMC-544; PF-5208773; WAY-207294

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; Apoptosis; CD22; DNA/RNA Synthesis

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Solubility

H2O

Smiles

[Inotuzumabozogamicin]

References & Citations

[1]Bruzzese A, et al. Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies. Eur J Haematol. 2025 Jun;114 (6) :938-952.